

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Form 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of March, 2020.

Commission File Number: **001-38524**

Titan Medical Inc.

(Exact Name of Registrant as Specified in Charter)

**155 University Avenue, Suite 750
Toronto, Ontario M5H 3B7
Canada**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3 on this Report on Form 6-K will be deemed to be incorporated by reference into the Registrant's Form F-3 registration statement filed on July 30, 2019 (File No. 333-232898).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

TITAN MEDICAL INC.
(Registrant)

Date: March 25, 2020

By: /s/ Stephen Randall
Name: Stephen Randall
Title: Chief Financial Officer

EXHIBIT INDEX

<u>99.1</u>	<u>Material Change Report Dated December 17, 2019</u>
<u>99.2</u>	<u>Material Change Report Dated January 16, 2020</u>
<u>99.3</u>	<u>Overview Presentation Dated March 23, 2020</u>

Form 51-102F3
Material Change Report

Item 1 Name and Address of Company

Titan Medical Inc. (the “Company” or “Titan”)
170 University Avenue
Suite 1000
Toronto, Ontario
M5H 3B3

Item 2 Date of Material Change

November 7, 2019 and November 27, 2019.

Item 3 News Release

The press releases attached as Schedule “A” and Schedule “B” were disseminated through Business Wire on November 7, 2019 and December 4, 2019 with respect to the material changes.

Item 4 Summary of Material Change

On November 7, 2019, the Company announced that it had decided not to proceed with the public offering of units of the Company for which it filed a final short form prospectus on October 31, 2019. The Company made this decision based on its assessment of market conditions, and intends to pursue alternative financing options.

On December 4, 2019 the Company announced that on November 27, 2019, the Company received notification from Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5550(a)(2) since the closing bid price for the Company’s common shares (the “Shares”) listed on Nasdaq was below US\$1.00 per Share for 30 consecutive business days.

The Company also received notification from the Nasdaq Listing Qualifications Department that it was not in compliance with the minimum Market Value of Listed Securities (“MVLS”) of US\$35 million requirement set forth in Nasdaq Rule 5550(b)(2) since the MVLS for the Shares listed on Nasdaq was below US\$35 million for 30 consecutive business days.

Item 5 Full Description of Material Change*5.1 Full Description of Material Change*

Please see the press releases attached as Schedule “A” and Schedule “B”.

5.2 Disclosure for Restructuring Transactions

Not applicable.

Item 6 Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable.

Item 7 Omitted Information

Not applicable.

Item 8 Executive Officer

The following executive officer is knowledgeable about the material changes and may be contacted about this report:

Stephen Randall
Chief Financial Officer
(416) 548-7522 (ext. 152)

Email: stephen@titanmedicalinc.com

Website: www.titanmedicalinc.com

Item 9 Date of Report

December 17, 2019.

Schedule "A"

[See Attached]

Titan Medical Determines Not to Proceed with Public Offering

TORONTO--(BUSINESS WIRE)--November 7, 2019--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announced today that it has determined not to proceed with the public offering of units of the Company for which it filed a final short form prospectus on October 31, 2019. The Company has made this decision based on its assessment of market conditions, and intends to pursue alternative financing options.

About Titan

Titan Medical Inc. is focused on computer-assisted robotic surgical technologies for application in MIS. The Company is developing a single-port robotic surgical system comprised of a surgeon-controlled patient cart that includes a dual-view camera system with 3D and 2D high-definition vision options and multi-articulating instruments for performing MIS procedures, and a surgeon workstation that provides an advanced ergonomic interface to the patient cart and a 3D endoscopic view inside the patient’s body. Titan intends to initially pursue gynecologic surgical indications for use of its single-port robotic surgical system.

For more information, please visit the Company’s website at www.titanmedicalinc.com.

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws. Such statements reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements, including with respect to the Company’s intention to pursue alternative financing options, reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the Company’s Annual Information Form dated March 29, 2019 (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, the Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Contacts

LHA Investor Relations

Kim Sutton Golodetz
(212) 838-3777
kgolodetz@lhai.com

or
Bruce Voss
(310) 691-7100
bvoss@lhai.com

Schedule "B"

[See Attached]

Titan Medical Confirms Receipt of Deficiency Notices From Nasdaq

TORONTO--(BUSINESS WIRE)--December 4, 2019--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery (“MIS”), today announced that on November 27, 2019, the Company received notification from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5550(a)(2) since the closing bid price for the Company's common shares (the “Shares”) listed on Nasdaq was below US\$1.00 for 30 consecutive business days. Nasdaq Rule 5550(a)(2) requires the Shares to maintain a minimum bid price of US\$1.00 per Share, and Nasdaq Rule 5810(c)(3)(A) provides that failure to meet such a requirement exists when the bid price of the Shares is below US\$1.00 for a period of 30 consecutive business days.

At the same time, the Company also received notification from the Nasdaq Listing Qualifications Department that it was not in compliance with the minimum Market Value of Listed Securities (“MVLS”) of US\$35 million requirement set forth in Nasdaq Rule 5550(b)(2) since the MLVS for the Shares listed on Nasdaq was below US\$35 million for 30 consecutive business days. Nasdaq Rule 5550(b)(2) requires the MLVS of the Shares to be at least US\$35 million, and Nasdaq Rule 5810(c)(3)(C) provides that failure to meet such a requirement exists when the MLVS of the Shares is below US\$35 million for a period of 30 consecutive business days.

These notifications do not impact the Company's listing on the Nasdaq Capital Market at this time. In accordance with Listing Rule 5810(c)(3)(A) and 5810(c)(3)(C), the Company has a period of 180 calendar days from the date of notification, being until May 25, 2020, to regain compliance with the minimum bid price and MVLS requirements, during which time the Shares will continue to trade on the Nasdaq Capital Market. If at any time before May 25, 2020, the bid price of the Shares closes at or above US\$1.00 per Share and the Company can achieve and maintain a MVLS of US\$35 million for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the minimum bid price and MVLS requirements and will consider such deficiency matters closed.

The Company is also listed on the Toronto Stock Exchange (the “TSX”) and the notification letter does not affect the Company's compliance status with the TSX.

The Company intends to evaluate all available options to resolve these deficiencies and regain compliance with Nasdaq Rules 5550(a)(2) and 5550(b)(2).

About Titan Medical Inc.

Titan Medical Inc. is focused on computer-assisted robotic surgical technologies for application in MIS. The Company is developing a single-port robotic surgical system comprised of a surgeon-controlled patient cart that includes a dual-view camera system with 3D and 2D high-definition vision options and multi-articulating instruments for performing MIS procedures, and a surgeon workstation that provides an advanced ergonomic interface to the patient cart and a 3D endoscopic view inside the patient's body. Titan intends to initially pursue gynecologic surgical indications for use of its single-port robotic surgical system.

For more information, please visit the Company's website at www.titanmedicalinc.com.

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws. Such statements reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements, including with respect to the Company’s intention to evaluate all available options to resolve the Nasdaq Rule 5550(a)(2) and 5550(b)(2) deficiencies, reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the Company’s Annual Information Form dated March 29, 2019 (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, the Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Contacts

LHA Investor Relations

Kim Sutton Golodetz

(212) 838-3777

kgolodetz@lhai.com

or

Bruce Voss

(310) 691-7100

bvoss@lhai.com

MATERIAL CHANGE REPORT
Form 51-102F3

Item 1 Name and Address of Company

Titan Medical Inc. (the “Company” or “Titan”)
170 University Avenue
Suite 1000
Toronto, Ontario
M5H 3B3

Item 2 Date of Material Change

December 23, 2019

Item 3 News Release

Attached as Schedule “A” is a copy of the news release relating to the material change, which was disseminated on December 23, 2019 through Business Wire and subsequently filed on the System for Electronic Document Analysis and Retrieval at www.sedar.com (“SEDAR”).

Item 4 Summary of Material Change

On December 23, 2019, the Company announced that it had entered into a Common Share Purchase Agreement (the “Agreement”) with Aspire Capital Fund, LLC (“Aspire Capital”) where Aspire Capital has committed to purchase up to US\$35.0 million of common shares of Titan at Titan’s request from time to time, until June 23, 2022. This new Agreement replaces the prior Common Share Purchase Agreement announced on August 29, 2019, which has been terminated upon entering into this Agreement.

Item 5 Full Description of Material Change

Please see the press release attached as Schedule “A”.

Item 6 Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable.

Item 7 Omitted Information

None.

Item 8 Executive Officer

The following executive officer is knowledgeable about the material changes and this report:

Stephen Randall
Chief Financial Officer
(416) 548-7522 (ext. 152)

Email: stephen@titanmedicalinc.com
Website: www.titanmedicalinc.com

Item 9 Date of Report

January 16, 2020

SCHEDULE "A"

See attached news release.

Titan Medical Announces New Common Share Purchase Agreement With Aspire Capital Fund of up to US\$35 Million

TORONTO--(BUSINESS WIRE)--December 23, 2019--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that it has entered into a Common Share Purchase Agreement (the “Agreement”) with Aspire Capital Fund, LLC (“Aspire Capital”) where Aspire Capital has committed to purchase up to US\$35.0 million of common shares of Titan at Titan’s request from time to time, until June 23, 2022. This new Agreement replaces the prior Common Share Purchase Agreement announced on August 29, 2019, which has been terminated upon entering into this Agreement.

Other terms of the Agreement provide that:

- Titan will control the timing and amount of the sale of its common shares to Aspire Capital.
 - On any business day, Titan shall have the right to direct Aspire Capital to purchase up to 100,000 common shares with a value not exceeding US\$500,000.
 - The purchase price shall be equal to the lesser of: (i) the lowest sale price of the common shares on Nasdaq on the purchase date, or (ii) the average of the three lowest closing sale prices of the common shares on Nasdaq during the 10 business days prior to the purchase date.
 - In addition to the regular purchases, Titan shall also have the right to require Aspire Capital to purchase up to an additional 30% of the trading volume of the common shares for the next business day at a purchase price equal to the lesser of: (i) the closing sale price of the common shares on Nasdaq on the purchase date, or (ii) 97% of the next business day’s volume weighted average price on Nasdaq (each such purchase, a “VWAP Purchase”). In no event shall the purchase price for a VWAP Purchase be lower than the maximum allowable discount allowed by the Toronto Stock Exchange (the “TSX”).
 - Titan shall have the right, in its sole discretion, to determine a maximum number of common shares and set a minimum market price threshold for each VWAP Purchase and there are no limits on the number of VWAP Purchases that Titan may require.
 - Aspire Capital will not be allowed to own more than 9.99% of the issued and outstanding common shares of the Company at any time without approval of the TSX.
 - The total number of common shares that may be issued under the Agreement shall not exceed 24.99% of the Company’s outstanding common shares as of the date of the Agreement unless the Company obtains shareholder approval in accordance with the rules of Nasdaq and the TSX.
 - In no event shall the purchase price for any common shares issuable under the Agreement be lower than the maximum allowable discount permitted by the TSX.
 - There are no warrants, derivatives, or other share classes associated with this Agreement.
-

Under the terms of the Agreement, Titan will immediately issue 973,000 common shares to Aspire Capital as a commitment fee (the “Commitment Shares”).

Any sale of common shares by Aspire Capital is expected to be made to arm’s length parties. There are no rights of first refusal, participation rights, penalties or liquidated damages in the Agreement. Titan maintains the right to terminate the Agreement at any time, at its discretion, without any additional cost or penalty.

Titan will file a prospectus supplement (the “Prospectus Supplement”) to the Company’s Form F-3 shelf registration statement (File No. 333-232898), which was declared effective on August 2, 2019 by the U.S. Securities and Exchange Commission, qualifying the offer and sale of common shares to Aspire Capital (including the Commitment Shares).

Under the Agreement, no common shares will be sold by Aspire Capital on the TSX or on other trading markets in Canada. The TSX has conditionally approved the issuance of common shares pursuant to the Agreement, and Nasdaq has completed its review pertaining to the listing of the common shares issuable under the Agreement and the Commitment Shares without any comments.

A copy of the Prospectus Supplement will be available on EDGAR at www.sec.gov or may be obtained upon request to Titan at the following address:

155 University Avenue, Suite 750
Toronto, Ontario M5H 3B7
Canada
Tel: (416) 548-7522
E-mail: info@titanmedicalinc.com

This press release does not constitute an offer to sell or the solicitation of any offer to purchase any securities, nor will there be any sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Titan Medical Inc.

Titan Medical Inc. is focused on computer-assisted robotic surgical technologies for application in MIS. The Company is developing a single-port robotic surgical system comprised of a surgeon-controlled patient cart that includes a dual-view camera system with 3D and 2D high-definition vision options and multi-articulating instruments for performing MIS procedures, and a surgeon workstation that provides an advanced ergonomic interface to the patient cart and a 3D endoscopic view inside the patient’s body. Titan intends to initially pursue gynecologic surgical indications for use of its single-port robotic surgical system.

For more information, please visit the Company's website at www.titanmedicalinc.com and on [EDGAR at www.sec.gov](http://www.sec.gov).

Forward-Looking Statements

This news release contains "forward-looking statements" which reflect the current expectations of management of the Company's future growth, results of operations, performance and business prospects and opportunities including statements concerning timing for filing the prospectus supplement, mechanics surrounding pricing and drawdowns on the facility, sales of common shares by Aspire and selling of shares on the TSX. Wherever possible, words such as "may", "would", "could", "will", "shall", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions, and include, without limitation, statements regarding: our continued eligibility to use the Form F-3 shelf registration statement; our ability to raise additional capital through the sale of common shares to Aspire Capital; and the sale of common shares by Aspire Capital to arm's length parties. Many factors could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the "Risk Factors" section of the Company's Annual Information Form dated March 29, 2019 (which may be viewed at www.sedar.com and at www.sec.gov). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure current or prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.

Contacts

LHA Investor Relations
Kim Sutton Golodetz
(212) 838-3777
kgolodetz@lhai.com
or
Bruce Voss
(310) 691-7100
bvoss@lhai.com



Overview Presentation

TSX: TMD | Nasdaq: TMDI

March 23, 2020

Forward-looking Statements

This presentation contains "forward-looking information" and "forward-looking statements" which relate to future events or future performance and reflect the current expectations and assumptions of management of the Company's future growth, results of operations, performance and business prospects, opportunities, and illustrations and prototypes of the SPORT Surgical Systems. Wherever possible, words such as "may", "would", "could", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "project", "predict", "target", "potential", and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance, achievements or technological development and implementation to be materially different from any future results, performance, achievements or technological development and implementation that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the "Risk Factors" section of the Company's Annual Information Form in respect of the fiscal year ended December 31, 2018, the additional risks set forth in the Company's management's discussion and analysis in respect of the three and nine months ended September 30, 2019, and other information contained in the Company's public filings (which may be viewed at www.sedar.com and at www.sec.gov). Information contained in this presentation is qualified in its entirety by such public filings. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this presentation. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the presentation are based upon what management currently believes to be reasonable assumptions as of the date of this presentation, there is no assurance that actual results, performance or achievements will be consistent with these forward-looking statements. This presentation does not constitute an offer to sell any class of securities of the Company in any jurisdiction. There is no assurance as to the whether hospitals will purchase at assumed prices. The Company does not forecast what portion of the total addressable market it will be able to capture.



Titan Medical Overview

Designer and developer of a versatile single-port platform for performing abdominal surgeries using robotic technology.


Designed for improved clinical performance,
ease-of-use, operating room efficiency
and hospital economics.



Investment Highlights

Novel Clinical Paradigm	✓ Multi-articulated instrument triangulation through a single incision
Promising Physician Feedback	✓ Tested by U.S. and EU surgeons from 4 surgical disciplines ✓ 45 preclinical studies prior to 15 GLP studies in 2019 ✓ 9 peer-reviewed abstract presentations and 1 published manuscript
Robust IP Portfolio	✓ 130+ global patents and applications
Disruptive Business Model	✓ Projected savings on capital equipment, service and procedure costs ✓ Recurring revenue model based on consumable components
Pre-commercial Momentum	✓ Focused Eastern U.S. launch planned using direct sales strategy
Favorable Market Dynamics	✓ Underpenetrated market due to size, complexity and costs associated with existing robotic surgical systems ✓ Applicable to multiple minimally invasive procedures

Evolution of Surgical Care



Today's Robotic Surgery Environment

Robotic technology was introduced to mitigate the risks of MIS, reduce variations in procedural efficiency and improve consistency of patient outcomes.

Benefits

- Increased Dexterity
- Improved Visualization (3D)
- Improved Ergonomics

Titan's single-port robotic system is being developed to offer the benefits of multi-articulated surgery through a single point of entry in order to reduce trauma.

Technology Differentiation

Engineered for Simplicity and Efficiency



Single-Incision

With a single incision made around the umbilicus, the result could potentially be near-scarless surgery




Small Footprint

Enhanced mobility and ease-of-use may lead to quicker deployment in multiple ORs and higher utilization



Multi-Articulating

Reusable multi-articulating instruments are designed for optimal triangulation and economical device performance



Open Display

3D high-definition display implemented to provide the balance of surgical immersion and situational awareness in the OR



Ergonomic Workstation

Highly ergonomic workstation with natural handle interface designed to enable comfortable surgical posture, even during long procedures



Purposeful Design

Designed from the ground up with the intent of improving:

Clinical Capabilities

OR Efficiency

Hospital Economics

System Overview

- Versatile single-port robotic surgery solution
- Smaller OR footprint than multi-port systems
- Designed to overcome multi-port robotic surgery limitations
- Engineered for performance, efficiency and cost-effectiveness
- Expected to provide access to underserved market segments, such as ambulatory surgery centers



Workstation



Integrated software for simulation training
(collaboration with Mimic Technologies, Inc.)

Natural multi-articulated
handle interface

Open, unobtrusive 3D
high-definition display

Multi-configurable elbow rest and
foot pedal positioning

Easily maneuverable with swiveling
easy-gliding coasters

Ergonomically focused design



Patient Cart

Easy to load and unload instruments through detachable camera insertion tube with integrated 2D high-definition camera


Single-port enables swift multi-quadrant positioning

Minimal cable management in OR

Single-arm configuration with no external moving parts facilitates simple setup and assistant-friendly surgery


Instruments and steerable 3D high-definition camera delivered through camera insertion tube of 25 mm diameter

Compact, rollers enable mobility to maneuver and position



Multi-Articulated Instruments

Variety of multi-use instruments and end effectors for grasping, suturing, cutting and coagulation




Open architecture for adaptation of future end effectors and functionality



Single-port surgery
with enhanced robotic
technology

Optimal Patient Care



Titan Medical's single-port surgical system is designed to provide surgeons with multi-articulated instruments in a triangulated configuration through a single incision.



Intellectual Property


A unique single-port robotic surgery system that is differentiated by its patented multi-articulating instruments, user interface and ergonomic features.

Differentiated and innovative design provides a strong position on freedom to operate.

49 U.S. & International Patents Issued

86 Applications Pending

Areas of Titan Medical's single-port robotic surgical system covered by patents or pending applications:



Proven Feasibility in a Wide Variety of Procedures

45 Procedures Performed to Date (*live porcine unless otherwise indicated, excludes GLP*)

- **GYN and GYN-ONC (8 procedures at Columbia University and Florida Hospital):**
 - Radical Hysterectomy with Bilateral Salpingo Oophorectomy and Bilateral Pelvic / Para-Aortic Node Dissection
 - Simple Hysterectomy with Bilateral Salpingo Oophorectomy and Bilateral Pelvic Node Dissection
 - Simple Hysterectomy with Bilateral Salpingo Oophorectomy
- **Urology (19 procedures at IHU Strasbourg and Florida Hospital):**
 - Hemi-Nephrectomy and Partial Nephrectomy
 - Prostatectomy (Human Cadaver)
 - Pyeloplasty
 - Ureteral-Bladder Anastomosis
- **General Surgery (14 procedures at IHU Strasbourg and Florida Hospital):**
 - Cholecystectomy (1 Human Cadaver, 5 Live Porcine)
 - Nissen Fundoplication (1 Human Cadaver, 3 Live Porcine)
 - Esophagectomy (Human Cadaver)
 - Gastrectomy
 - Splenectomy
- **Colorectal (4 procedures at Florida Hospital):**
 - Colectomy
 - Low Anterior Resection



Peer-reviewed Abstracts to Date

Single-port robotic surgery with Titan's system is feasible & repeatable.

- 1. Multi-disciplinary applications of a new robotic platform** by Barbara Seeliger, MD and Lee Swanstrom, MD (IHU Strasbourg)
Accepted and presented at Society of American Gastrointestinal and Endoscopic Surgeons Meeting, Seattle, WA, April 2018
- 2. Single-port prostatectomy using SPORT Surgical System** by Eric Barret, MD (IMM, France)
Accepted and presented at EAU Section of Urology Technology Meeting, Modena, Italy, May 2018
- 3. Multispecialty single port robotic technology applied in the live animal model: proof of concept** by Travis Rogers, MD, Eduardo Parra Davila, MD, Vipul Patel, MD (all from Florida Hospital), Ricardo Estape, MD (South Miami GOG) and Armando Melani, MD (IRCAD Brazil)
Accepted and presented as a poster at Society of Robotic Surgery Meeting, Stockholm, Sweden, June 2018
- 4. Feasibility of single-port partial nephrectomy using SPORT surgical system** by Eric Barret, MD (IMM, France)
Accepted and presented as a poster at Society of Robotic Surgery Meeting, Stockholm, Sweden, June 2018
- 5. Single-port robotic partial and hemi nephrectomy using a novel single port robotic platform** by Sebastien Crouzet, MD (University of Lyon, France) and Barbara Seeliger, MD (IHU Strasbourg)
Accepted and presented at EAU Robotic Urology Section Meeting, Marseille, France, September 2018
- 6. Reverse Objective Structured Assessment of Technical Skills (Reverse-OSATS) as a means of measuring the capability of the Titan Medical SPORT Surgical System on core surgical principles** by Chetna Arora, MD, Arnold P. Advincula, MD (both from Columbia University Medical Center) and William B. Burke, MD (Stony Brook Cancer Center)
Accepted and presented at Society of European Robotic Gynecologic Surgeons Meeting, Milan, Italy, September 2018
- 7. Multispecialty single port robotic technology applied in the live animal model: proof of concept** by Travis Rogers, MD, Eduardo Parra Davila, MD, Vipul Patel, MD (all from Florida Hospital), Ricardo Estape, MD (South Miami GOG) and Armando Melani, MD (IRCAD Brazil)
Accepted and presented at World Congress of Endourology Meeting, Paris, France, September 2018
- 8. Feasibility of single-port partial nephrectomy using SPORT surgical system** by Eric Barret, MD (IMM, France)
Accepted and presented at World Congress of Endourology Meeting, Paris, France, September 2018
- 9. Reverse Objective Structured Assessment of Technical Skills (Reverse-OSATS) as a means of measuring the capability of the Titan Medical SPORT Surgical System on core surgical principles** by Chetna Arora, MD, Arnold P. Advincula, MD (both from Columbia University Medical Center) and William B. Burke, MD (Stony Brook Cancer Center)
Accepted and presented at American Association of Gynecologic Laparoscopists Global Congress, Las Vegas, NV, November 2018



Published Manuscript

Surgical Endoscopy

Enabling single-site laparoscopy: the SPORT platform

Barbara Seeliger¹ · Michele Diana¹ · Jelle P. Ruurda² · Konstantinos M. Konstantinidis³ · Jacques Marescaux¹ · Lee L. Swanström^{1,4}

¹ IHU-Strasbourg Institute of Image-Guided Surgery, 1, place de l'Hôpital, 67091 Strasbourg Cedex, France

² Department of Surgical Oncology, University Medical Center, Utrecht, Utrecht, Netherlands

³ Department of General, Bariatric, Laparoscopic and Robotic Surgery, Athens Medical Center, Athens, Greece

⁴ Division of GI/MIS, The Oregon Clinic, Portland, OR, USA



Initial U.S. Target: Benign Gynecologic Surgery

- Rationale:
 - Potential to reduce trauma and scarring, and offers possibility of faster recovery for an engaged patient population
 - Ability to produce positive patient outcomes in relatively low-risk benign procedures
 - Viable alternative to other single-port approaches based on gynecologic surgeon feedback from preclinical studies
 - Attractive procedure volumes performed in outpatient as well as inpatient settings, favoring smaller footprint and lower-cost model
 - Clarity of regulatory pathway
 - With an initial U.S. focus, an ability to efficiently provide comprehensive product training and support to facilitate early product adoption and consistent, successful outcomes





Summary

- Highly versatile, differentiated advanced single-port robotic platform
- Designed for improved clinical performance, ease of use, operating room efficiency and hospital economics
- Potential benefits to patients, surgeons and hospitals versus competitive offerings
- System performance verified in preclinical studies with data presented at clinical conferences
- Experienced management team with a record of success



Thank You

TSX: TMD | Nasdaq: TMDI